Panobinostat: A novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma

Expert Review of Anticancer Therapy

Volumn 15, Issue 7, 2015, Pages 737-748

  Richardson, Paul G ^a   Laubach, Jacob P ^a   Lonial, Sagar ^b   Moreau, Philippe ^c   Yoon, Sung Soo ^d   Hungria, Vânia T ^e   Dimopoulos, Meletios A ^f   Beksac, Meral ^g   Alsina, Melissa ^h   San Miguel, Jesús F ⁱ  

^a HARVARD MEDICAL SCHOOL   (United States)

^b EMORY UNIVERSITY   (United States)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d Seoul National University Hospital   (South Korea)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^g ANKARA UNIVERSITY   (Turkey)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

bortezomib; deacetylase inhibitors; multiple myeloma; panobinostat; treatment of relapsed and refractory disease

Indexed keywords

BORTEZOMIB; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXAMETHASONE; GLUTATHIONE PEROXIDASE 3; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 6; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LENALIDOMIDE; OSTEONECTIN; PANOBINOSTAT; PLACEBO; PROTEIN KINASE B; RICOLINOSTAT; STAT3 PROTEIN; TETRASPANIN; THALIDOMIDE; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER RECURRENCE; CELL CYCLE PROGRESSION; COHORT ANALYSIS; CONTINUOUS INFUSION; DIARRHEA; DNA REPLICATION; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; FATIGUE; GASTROINTESTINAL DISEASE; GENE; GENE DISRUPTION; GENE EXPRESSION; GPX3 GENE; HEMATOLOGIC DISEASE; HISTONE ACETYLATION; HODGKIN DISEASE; HUMAN; IN VITRO STUDY; INCIDENCE; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RBP1 GENE; SINGLE DRUG DOSE; SPARC GENE; TGRBI GENE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPREGULATION; VOMITING; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; MORTALITY; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; CLINICAL TRIALS AS TOPIC; DEXAMETHASONE; DISEASE-FREE SURVIVAL; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; MULTIPLE MYELOMA;

EID: 84933518228     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.1047770     Document Type: Article

References (42)

1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15(12):e538-48.
2. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364(11): 1046-60
3. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin 2014;64(1): 9-29
4. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012;26(1):149-57.
5. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28(5):1122-8
6. Offidani M, Corvatta L, Caraffa P, et al. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data. Expert Rev Anticancer Ther 2014;14(5): 499-510
7. Pautasso C, Bringhen S, Cerrato C, et al. The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol 2013;9(10):1371-9
8. DeAngelo DJ, Spencer A, Bhalla KN, et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 2013;27(8):1628-36
9. Ocio EM, Vilanova D, Atadja P, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 2010;95(5):794-803
10. Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006;108(10): 3441-9
11. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther 2011;10(11):2034-42
12. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 2009;280(2): 233-41
13. Wolf JL, Siegel D, Goldschmidt H, et al. A phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma 2012;53(9): 1820-3
14. Clive S, Woo MM, Nydam T, et al. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Cancer Chemother Pharmacol 2012;70(4):513-22
15. San-Miguel JF, Richardson PG, Gunther A, et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 2013;31(29):3696-703
16. Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009;325(5942):834-40
17. Guarente L. Sirtuins in aging and disease. Cold Spring Harb Symp Quant Biol 2007;72:483-8
18. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007;1(1):19-25
19. Kaiser MF, Johnson DC, Wu P, et al. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood 2013;122(2): 219-26
20. Mithraprabhu S, Kalff A, Chow A, et al. Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics 2014;9(11):1511-20.
21. Kalushkova A, Fryknas M, Lemaire M, et al. Polycomb target genes are silenced in multiple myeloma. PLoS ONE 2010;5(7): e11483
22. Moreaux J, Reme T, Leonard W, et al. Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. Br J Cancer 2013; 109(3):676-85
23. De Bruyne E, Bos TJ, Asosingh K, et al. Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival. Clin Cancer Res 2008;14(10):2918-26
24. San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014;15(11):1195-206
25. Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013;122(14):2331-7
26. Richardson PG, Schlossman RL, Alsina M, et al. Time to event analyses in PANORAMA 2: a phase 2 study of panobinostat, bortezomib, and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma. American Society of Hematology Annual Meeting. 2013, New Orleans, LA
27. Farydak-prescribing information. Novartis Pharmaceuticals Corporation. 2015. Available from: www.accessdata.fda.gov/drugsatfda-docs/label/2015/205353s000lbl. pdf?et-cid=35529885&et-rid=933034278 &linkid=http%3a%2f%2fwww.accessdata. fda.gov%2fdrugsatfda-docs%2flabel% 2f2015%2f205353s000lbl.pdf [Last accessed 25 February 2015]
28. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, noninferiority study. Lancet Oncol 2013;12(5):431-40
29. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010;116(23):4745-53
30. A Phase I study of the combination of panobinostat and carfilzomib in patients with relapsed and/or refractory multiple myeloma. Available from: https://clinicaltrials.gov/ct2/show/NCT01549431
31. Study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Available from: https://clinicaltrials.gov/ct2/show/NCT01496118
32. Carfilzomib plus panobinostat in relapsed/refractory multiple myeloma (MM). Available from: https://clinicaltrials.gov/ct2/show/NCT01301807
33. MLN9708 (Ixazomib) in combination with panobinostat and dexamethasone in multiple myeloma. Available from: https://clinicaltrials.gov/ct2/show/NCT02057640
34. Berdeja JG, Hart LL, Mace JR, et al. Phase I/II Study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica 2015. [Epub ahead of print]
35. Kaufman J, Zimmerman T, Rosenbaum C, et al. Phase I study of the combination of carfilzomib and panobinostat for patients with relapsed and refractory myeloma: A Multiple Myeloma Research Consortium (MMRC) clinical trial. American Society of Hematology Annual Meeting. 2014, San Francisco, CA
36. Shah JJ, Thomas SK, Weber DM, et al. Phase 1/1b study of the efficacy and safety of the combination of panobinostat + carfilzomib in patients with relapsed and/or refractory multiple myeloma. American Society of Hematology Annual Meeting. 2012, Atlanta, GA
37. Phase II, single-center, oral panobinostat in combination with lenalidomide and dexamethasone in multiple myeloma (MM). Available from: https://clinicaltrials.gov/ct2/show/NCT01651039
38. Velcade, thalidomide, dexamethasone and panobinostat treatment and panobinostat maintenance in multiple myeloma (MUKsix). Available from: https://clinicaltrials.gov/ct2/show/NCT02145715
39. Combination therapy of lenalidomide/bortezomib/dexamethasone and panobinostat in transplant eligible new diagnosed multiple myeloma (MM) Patients. Available from: https://clinicaltrials. gov/ct2/show/NCT01440582
40. A Phase I study of panobinostat/lenalidomide/bortezomib/dex for relapsed and relapsed/refractory multiple myeloma (PanRVD). Available from: https://clinicaltrials.gov/ct2/show/NCT01965353
41. Ocio EM, Davila J, Caballero JC, et al. Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma. Haematologica 2015; Epub ahead of print
42. Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012;119(11):2579-89